跳至主導覽
跳至搜尋
跳過主要內容
長庚大學學術能量集萃 首頁
說明與常見問題
English
中文
首頁
學者概覽
研究單位
研究產出
研究計畫-專案
獎項
活動
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
黃 文冠
臨床助理教授
,
醫學系
電子郵件
D000018678
cgu.edu
tw
h-index
h10-index
h5-index
755
引文
15
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
683
引文
14
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
354
引文
11
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2012
2024
每年研究產出
概覽
指紋
網絡
研究計畫-專案
(5)
研究產出
(70)
相近領域學者
(6)
指紋
查看啟用 Wen-Kuan Huang 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Medicine and Dentistry
Patient
100%
Inpatient
69%
Malignant Neoplasm
46%
Cohort Analysis
33%
Survival
29%
Therapeutic Procedure
28%
Chemotherapy
26%
Incidence
26%
Colorectal Cancer
20%
Circulating Tumor Cell
18%
Prostate Cancer
18%
Hazard Ratio
17%
Cells
16%
Progression Free Survival
15%
Prognostic Factor
15%
Overall Survival
14%
Association
14%
Follow up
14%
Mortality
14%
Diagnosis
14%
Nodular Melanoma
13%
Cholangiocarcinoma
13%
Gastrointestinal Stromal Tumor
13%
Oncology
12%
Prognosis
11%
Age
11%
Combination Therapy
11%
Adult
10%
Cardiovascular Disease
10%
Biological Marker
10%
Androgen Deprivation Therapy
10%
Neoplasm
9%
Experience
9%
Brain Ischemia
9%
Dementia
9%
Pyogenic Liver Abscess
9%
Acetylsalicylic Acid
9%
Metastatic Breast Cancer
9%
Chemoradiotherapy
9%
Immune Checkpoint Inhibitor
9%
Compassionate Use
9%
Low Drug Dose
8%
Cardiovascular System
7%
Health
7%
Immunoglobulin
6%
Major Bleeding
6%
Gemcitabine
6%
Targeted Therapy
6%
Survival Rate
6%
Orchiectomy
6%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
36%
Neoplasm
20%
Survival
18%
Prostate Cancer
18%
Gemcitabine
15%
Incidence
15%
Gastrointestinal Stromal Tumor
13%
Androgen
13%
Bile Duct Carcinoma
13%
Colorectal Cancer
11%
Cohort Study
11%
Prognosis
9%
Cardiovascular Disease
9%
Chemotherapy
9%
Biological Marker
9%
Overall Survival
9%
Dementia
9%
Metastatic Breast Cancer
9%
Biliary Tract Cancer
9%
Hand Foot Syndrome
9%
Diseases
8%
Gonadorelin Agonist
8%
Mortality
7%
Protein Tyrosine Kinase Inhibitor
7%
Imatinib
6%
Brain Ischemia
6%
Protein P53
6%
Progression Free Survival
6%
Metastatic Colorectal Cancer
6%
Zinc Deficiency
6%
Gonadorelin Antagonist
5%
Regorafenib
5%
Protein
5%
Apoptosis
5%
microRNA
5%
Heart Failure
5%
Interleukin 2
5%
Venous Thromboembolism
5%
Angiotensin Receptor Antagonist
5%
Cancer Risk
5%
Mortality Rate
5%
Cardiovascular Risk
5%
Biochemistry, Genetics and Molecular Biology
Mutation
16%
Survival
16%
Immune Checkpoints
15%
Imatinib
13%
Overall Survival
12%
Progression Free Survival
12%
Gene Signature
10%
Microsatellite Instability
7%
Data Base
7%
Cell Count
6%
P53
6%
Bioinformatics
6%
Regulatory Mechanism
5%
Nested Gene
5%
Association
5%
Cohort Study
5%
